Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 29th July 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer Ingelheim acquires Global Stem Cell Technology
Jan Spaas, CEO of GST.
Acquisition follows two years of successful partnership. 

Boehringer Ingelheim has acquired Global Stem Cell Technology (GST), a Belgian biotech firm that develops stem cell products for dogs and horses.

The acquisition follows Boehringer Ingelheim's partnership with GST in 2018. In 2019, the companies launched Arti-Cell® Forte in Europe, the first-ever stem cell product in the veterinary sphere granted marketing authorisation by the European Commission.

In a press release, Boehringer Ingelheim states that the acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health, commented: "Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the-art stem cell products will help us bring even more innovative solutions to our customers."

Jan Spaas, CEO of GST added: “Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GST’s management, staff and vision. From the very beginning, we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim,”

The financial terms of the deal have not been disclosed. 

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
New guidance for antibiotic use in rabbits

New best practice guidance on the responsible use of antibiotics in rabbits has been published by the BSAVA in collaboration with the Rabbit Welfare Association & Fund (RWA&F).

The guidance is free and has been produced to help veterinary practitioners select the most appropriate antibiotic for rabbits. It covers active substance, dose and route of administration all of which are crucial factors when treating rabbits owing to the risk of enterotoxaemia.

For more information and to access the guide, visit the BSAVALibrary.